CytomX Therapeutics, Inc.
CTMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001501989
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
178
- −1 vs. Q1 2026
- Total value $800.36M
Superinvestors holding CTMX
0
- None of the superinvestors held CTMX at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by CTMX insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Jun 15, 2026 | Ogden ChristopherChief Financial Officer | SSaleCommon Stock | −1.62K | $3.05 | −$4.95K | 295.32K | −0.5% | SEC |
| Mar 19, 2026 | Mar 17, 2026 | Chu Yu-WayeChief Medical Officer | SSaleCommon Stock | −21.28K | $6.42 | −$136.61K | 189.45K | −10.1% | SEC |
| Mar 19, 2026 | Mar 17, 2026 | McCarthy Sean A.CEO | SSaleCommon Stock | −118.97K | $6.42 | −$763.78K | 1.08M | −9.9% | SEC10b5-1 |
| Mar 19, 2026 | Mar 17, 2026 | BELVIN MARCIASVP, Chief Scientific Officer | SSaleCommon Stock | −31.49K | $6.42 | −$202.18K | 300.76K | −9.5% | SEC |
| Mar 19, 2026 | Mar 17, 2026 | Ogden ChristopherChief Financial Officer | SSaleCommon Stock | −19.32K | $6.42 | −$124.05K | 296.95K | −6.1% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in CTMX at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 32,714,937 | $122.68M | 0.01% | +759,300+2.4% | Added |
| Kynam Capital Management, LP | 21,703,093 | $81.39M | 4.50% | +6,690,000+44.6% | Added |
| BlackRock, Inc. | 17,559,822 | $65.85M | 0.00% | +12,331,542+235.9% | Added |
| BANK OF AMERICA CORP /DE/ | 15,082,617 | $56.56M | 0.00% | +4,879,832+47.8% | Added |
| STATE STREET CORP | 11,747,236 | $44.05M | 0.00% | +6,083,828+107.4% | Added |